榄香烯注射液联合放化疗治疗胶质母细胞瘤  

Therapeutic effects of β-elemene in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma： a pilot study

作　　者：马春晓[1] 周伟[1] 闫兆月[1] 屈鸣麒[1] 步星耀[1] 刘建波[2] 王伟[2] 

机构地区：[1]郑州大学人民医院(河南省人民医院)神经外科,450003 [2]郑州大学人民医院(河南省人民医院)放疗科,450003

出　　处：《中华实验外科杂志》2016年第9期2093-2095,共3页Chinese Journal of Experimental Surgery

摘　　要：目的 探讨榄香烯对胶质母细胞瘤（GBM）的治疗作用.方法 回顾性分析2009年7月至2014年7月河南省人民医院神经外科收治的63例GBM患者的病历资料,其中替莫唑胺同步放化疗和辅助化疗（RT＋ TMZ组）35例,在此治疗基础上接受榄香烯治疗者（RT＋ TMZ＋ ELE组）28例,比较两组患者总体生存、无进展生存以及不良反应的发生情况.结果 Kaplan-Meier生存分析结果显示,与RT＋ TMZ组比较,RT＋ TMZ＋ ELE组患者总体生存率（χ^2=18.034,P＜0.01）和无进展生存率（χ^2 =54.443,P＜0.01）均较好;RT＋ TMZ组和RT＋ TMZ＋ ELE组患者中位生存时间分别为18个月和21个月,无进展生存时间为8个月和11个月.血液学毒性反应在RT＋ TMZ组和RT＋ TMZ＋ ELE组分别发生10例和2例,差异有统计学意义（χ^2=4.559,P＜0.05）.结论 榄香烯治疗可以明显改善GBM患者预后生存,抑制术后进展,且能够降低放化疗相关血液学毒性反应的发生。Objective To explore the potential therapeutic effects of β-elemene in patients with glioblastoma.Methods 63 patients with newly diagnosed primary glioblastoma （GBM）,hospitalized in the department of neurosurgery of Henan Provincial People＆#39; s Hospital from July,2009 to July,2014,were retrospectively reviewed.All the patients received concomitant chemoradiotherapy （RT） and adjuvant chemotherapy with temizolomide （TMZ）.35 patients received RT ＋ TMZ treatment alone （RT ＋ TMZ group）.28 patients received additional β-elemene treatment （RT ＋ TMZ ＋ ELE group）.Kaplan-Meier survival analyses were performed to compare the overall survival （OS） and progression-free survival （PFS） between the two groups.The occurrence of the adverse effects in the two groups were also compared.Results Kaplan-Meier survival analysis indicated that the overall survival （χ^2 =18.034,P 〈 0.01） and progression-free survival （χ^2 =54.443,P 〈 0.01） were both improved in RT ＋ TMZ ＋ ELE group compared with RT ＋ TMZ group.The median overall survival and progression-free survival of the patients in the RT ＋ TMZ ＋ ELE group were 21 months and 11 months respectively,significantly longer than those patients in RT ＋ TMZ group （Median OS：18 months;Median PFS：8 months）.28.6% （10 cases） of patients presented hematologic toxic events in the RT ＋ TMZ group,significantly higher than that in RT ＋ TMZ ＋ ELE group （7.1%,2 cases;χ^2 =4.559,P 〈 0.05）.The occurrence of other adverse effects in the two groups showed no significant difference.Conclusion β-elemene treatment could improve the prognosis of the glioblastoma and inhibit its postoperative progression.It could also inhibit the occurrence of hematologic toxic effects.

关 键 词：榄香烯 替莫唑胺 胶质母细胞瘤 放射治疗 

分 类 号：R979.1[医药卫生—药品]